Skip to main content
Top
Published in: Pituitary 1/2014

Open Access 01-01-2014

Multiple facets in the control of acromegaly

Authors: Lucio Vilar, Alex Valenzuela, Antônio Ribeiro-Oliveira Jr., Claudia M. Gómez Giraldo, Doly Pantoja, Marcello D. Bronstein

Published in: Pituitary | Special Issue 1/2014

Login to get access

Abstract

Aims

The current article provides a brief overview of the criteria for defining disease control in acromegaly.

Methods

This was a retrospective, narrative review of previously published evidence chosen at the author’s discretion along with an illustrative case study from Latin America.

Findings and Conclusions

In the strictest sense, “cure” in acromegaly is defined as complete restoration of normal pulsatile growth hormone secretion, although this is rarely achieved. Rather than “cure”, as such, it is more appropriate to refer to disease control and remission, which is defined mainly in terms of specific biochemical targets (for growth hormone and insulin-like growth factor-1) that predict or correlate with symptoms, comorbidities and mortality. However, optimal management of acromegaly goes beyond biochemical control to include control of tumour growth (which may be independent of biochemical control) and comprehensive management of the symptoms and comorbidities typically associated with the disease, as these may not be adequately managed with acromegaly-specific therapy alone.
Literature
2.
go back to reference Clemmons DR (2011) Clinical laboratory indices in the treatment of acromegaly. Clin Chim Acta 412(5–6):403–409PubMedCrossRef Clemmons DR (2011) Clinical laboratory indices in the treatment of acromegaly. Clin Chim Acta 412(5–6):403–409PubMedCrossRef
3.
go back to reference Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S, Acromegaly Consensus Group (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95(7):3141–3148PubMedCrossRef Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S, Acromegaly Consensus Group (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95(7):3141–3148PubMedCrossRef
5.
go back to reference Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A, Acromegaly Consensus Group (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94(5):1509–1517PubMedCrossRef Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A, Acromegaly Consensus Group (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94(5):1509–1517PubMedCrossRef
6.
go back to reference Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK, AACE Acromegaly Task Force (2011) American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly–2011 update: executive summary. Endocr Pract 17(4):636–646PubMedCrossRef Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK, AACE Acromegaly Task Force (2011) American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly–2011 update: executive summary. Endocr Pract 17(4):636–646PubMedCrossRef
7.
go back to reference Trainer PJ, Barth J, Sturgeon C, Wieringaon G (2006) Consensus statement on the standardisation of GH assays. Eur J Endocrinol 155(1):1–2PubMedCrossRef Trainer PJ, Barth J, Sturgeon C, Wieringaon G (2006) Consensus statement on the standardisation of GH assays. Eur J Endocrinol 155(1):1–2PubMedCrossRef
8.
go back to reference Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ (2007) Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol (Oxf) 67(1):65–70CrossRef Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ (2007) Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol (Oxf) 67(1):65–70CrossRef
9.
go back to reference Clemmons DR (2007) IGF-I assays: current assay methodologies and their limitations. Pituitary 10(2):121–128PubMedCrossRef Clemmons DR (2007) IGF-I assays: current assay methodologies and their limitations. Pituitary 10(2):121–128PubMedCrossRef
11.
go back to reference Massart C, Poirier JY (2006) Serum insulin-like growth factor-I measurement in the follow-up of treated acromegaly: comparison of four immunoassays. Clin Chim Acta 373(1–2):176–179PubMedCrossRef Massart C, Poirier JY (2006) Serum insulin-like growth factor-I measurement in the follow-up of treated acromegaly: comparison of four immunoassays. Clin Chim Acta 373(1–2):176–179PubMedCrossRef
12.
go back to reference Holdaway IM, Bolland MJ, Gamble GD (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159(2):89–95PubMedCrossRef Holdaway IM, Bolland MJ, Gamble GD (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159(2):89–95PubMedCrossRef
13.
go back to reference Chanson P, Maison P (2009) Does attainment of target levels of growth hormone and insulin-like growth factor I improve acromegaly prognosis? Nat Clin Pract Endocrinol Metab 5(2):70–71PubMedCrossRef Chanson P, Maison P (2009) Does attainment of target levels of growth hormone and insulin-like growth factor I improve acromegaly prognosis? Nat Clin Pract Endocrinol Metab 5(2):70–71PubMedCrossRef
14.
go back to reference Freda PU (2009) Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clin Endocrinol (Oxf) 71(2):166–170CrossRef Freda PU (2009) Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clin Endocrinol (Oxf) 71(2):166–170CrossRef
15.
go back to reference Puder JJ, Nilavar S, Post KD, Freda PU (2005) Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab 90(4):1972–1978PubMedCrossRef Puder JJ, Nilavar S, Post KD, Freda PU (2005) Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab 90(4):1972–1978PubMedCrossRef
16.
go back to reference Biermasz N (2010) Pituitary gland: new consensus in acromegaly: criteria for cure and control. Nat Rev Endocrinol 6(9):480–481PubMedCrossRef Biermasz N (2010) Pituitary gland: new consensus in acromegaly: criteria for cure and control. Nat Rev Endocrinol 6(9):480–481PubMedCrossRef
17.
go back to reference Carmichael JD, Bonert VS, Mirocha JM, Melmed S (2009) The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 94(2):523–527PubMedCrossRef Carmichael JD, Bonert VS, Mirocha JM, Melmed S (2009) The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 94(2):523–527PubMedCrossRef
18.
go back to reference Sherlock M, Aragon Alonso A, Reulen RC, Ayuk J, Clayton RN, Holder G, Sheppard MC, Bates A, Stewart PM (2009) Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly. Clin Endocrinol (Oxf) 71(1):74–81CrossRef Sherlock M, Aragon Alonso A, Reulen RC, Ayuk J, Clayton RN, Holder G, Sheppard MC, Bates A, Stewart PM (2009) Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly. Clin Endocrinol (Oxf) 71(1):74–81CrossRef
19.
go back to reference Ribeiro-Oliveira A Jr, Faje AT, Barkan AL (2011) Limited utility of oral glucose tolerance test in biochemically active acromegaly. Eur J Endocrinol 64(1):17–22CrossRef Ribeiro-Oliveira A Jr, Faje AT, Barkan AL (2011) Limited utility of oral glucose tolerance test in biochemically active acromegaly. Eur J Endocrinol 64(1):17–22CrossRef
20.
go back to reference Ribeiro-Oliveira A Jr, Faje A, Barkan A (2011) Postglucose growth hormone nadir and insulin-like growth factor-1 in naïve-active acromegalic patients: do these parameters always correlate? Arq Bras Endocrinol Metabol 55(7):494–497PubMedCrossRef Ribeiro-Oliveira A Jr, Faje A, Barkan A (2011) Postglucose growth hormone nadir and insulin-like growth factor-1 in naïve-active acromegalic patients: do these parameters always correlate? Arq Bras Endocrinol Metabol 55(7):494–497PubMedCrossRef
21.
go back to reference Grottoli S, Gasco V, Ragazzoni F, Ghigo E (2003) Hormonal diagnosis of GH hypersecretory states. J Endocrinol Invest 26(10 Suppl):27–35PubMed Grottoli S, Gasco V, Ragazzoni F, Ghigo E (2003) Hormonal diagnosis of GH hypersecretory states. J Endocrinol Invest 26(10 Suppl):27–35PubMed
22.
go back to reference Casarini AP, Pinto EM, Jallad RS, Giorgi RR, Giannella-Neto D, Bronstein MD (2006) Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest 29(9):826–830PubMed Casarini AP, Pinto EM, Jallad RS, Giorgi RR, Giannella-Neto D, Bronstein MD (2006) Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest 29(9):826–830PubMed
23.
go back to reference Resmini E, Dadati P, Ravetti JL, Zona G, Spaziante R, Saveanu A, Jaquet P, Culler MD, Bianchi F, Rebora A, Minuto F, Ferone D (2007) Rapid pituitary tumour shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 92(5):1592–1599PubMedCrossRef Resmini E, Dadati P, Ravetti JL, Zona G, Spaziante R, Saveanu A, Jaquet P, Culler MD, Bianchi F, Rebora A, Minuto F, Ferone D (2007) Rapid pituitary tumour shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 92(5):1592–1599PubMedCrossRef
24.
go back to reference Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S (2012) Meta-analysis on the effects of octreotide on tumour mass in acromegaly. PLoS ONE 7(5):e36411PubMedCentralPubMedCrossRef Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S (2012) Meta-analysis on the effects of octreotide on tumour mass in acromegaly. PLoS ONE 7(5):e36411PubMedCentralPubMedCrossRef
25.
go back to reference Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A (2005) A critical analysis of pituitary tumour shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90(7):4405–4410PubMedCrossRef Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A (2005) A critical analysis of pituitary tumour shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90(7):4405–4410PubMedCrossRef
26.
go back to reference Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C (2002) Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 56(1):65–71CrossRef Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C (2002) Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 56(1):65–71CrossRef
27.
go back to reference Bevan JS (2005) Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90(3):1856–1863PubMedCrossRef Bevan JS (2005) Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90(3):1856–1863PubMedCrossRef
28.
go back to reference Sandret L, Maison P, Chanson P (2011) Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 96(5):1327–1335PubMedCrossRef Sandret L, Maison P, Chanson P (2011) Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 96(5):1327–1335PubMedCrossRef
29.
go back to reference Mazziotti G, Giustina A (2010) Effects of lanreotide SR and Autogel on tumour mass in patients with acromegaly: a systematic review. Pituitary 13(1):60–67PubMedCrossRef Mazziotti G, Giustina A (2010) Effects of lanreotide SR and Autogel on tumour mass in patients with acromegaly: a systematic review. Pituitary 13(1):60–67PubMedCrossRef
30.
go back to reference Annamalai AK, Webb A, Kandasamy N, Elkhawad M, Moir S, Khan F, Maki-Petaja K, Gayton EL, Strey CH, O’Toole S, Ariyaratnam S, Halsall DJ, Chaudhry AN, Berman L, Scoffings DJ, Antoun NM, Dutka DP, Wilkinson IB, Shneerson JM, Pickard JD, Simpson HL, Gurnell M (2013) A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J Clin Endocrinol Metab 98(3):1040–1050PubMedCrossRef Annamalai AK, Webb A, Kandasamy N, Elkhawad M, Moir S, Khan F, Maki-Petaja K, Gayton EL, Strey CH, O’Toole S, Ariyaratnam S, Halsall DJ, Chaudhry AN, Berman L, Scoffings DJ, Antoun NM, Dutka DP, Wilkinson IB, Shneerson JM, Pickard JD, Simpson HL, Gurnell M (2013) A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J Clin Endocrinol Metab 98(3):1040–1050PubMedCrossRef
31.
go back to reference Moore DJ, Adi Y, Connock MJ, Bayliss S (2009) Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. BMC Endocr Disord 9:20PubMedCentralPubMedCrossRef Moore DJ, Adi Y, Connock MJ, Bayliss S (2009) Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. BMC Endocr Disord 9:20PubMedCentralPubMedCrossRef
32.
go back to reference van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, Hey-Hadavi J, Lundgren F, Rajicic N, Strasburger CJ, Webb SM, Koltowska-Häggström M (2012) Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 97(5):1589–1597PubMedCrossRef van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, Hey-Hadavi J, Lundgren F, Rajicic N, Strasburger CJ, Webb SM, Koltowska-Häggström M (2012) Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 97(5):1589–1597PubMedCrossRef
33.
go back to reference Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25(1):102–152PubMedCrossRef Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25(1):102–152PubMedCrossRef
34.
go back to reference Lombardi G, Galdiero M, Auriemma RS, Pivonello R, Colao A (2006) Acromegaly and the cardiovascular system. Neuroendocrinology 83(3–4):211–217PubMedCrossRef Lombardi G, Galdiero M, Auriemma RS, Pivonello R, Colao A (2006) Acromegaly and the cardiovascular system. Neuroendocrinology 83(3–4):211–217PubMedCrossRef
35.
go back to reference Colao A, Pivonello R, Grasso LF, Auriemma RS, Galdiero M, Savastano S, Lombardi G (2011) Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. Eur J Endocrinol 165(5):713–721PubMedCrossRef Colao A, Pivonello R, Grasso LF, Auriemma RS, Galdiero M, Savastano S, Lombardi G (2011) Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. Eur J Endocrinol 165(5):713–721PubMedCrossRef
36.
go back to reference Lombardi G, Di Somma C, Grasso LF, Savanelli MC, Colao A, Pivonello R (2012) The cardiovascular system in GH excess and GH deficiency. J Endocrinol Invest 35(11):1021–1029PubMed Lombardi G, Di Somma C, Grasso LF, Savanelli MC, Colao A, Pivonello R (2012) The cardiovascular system in GH excess and GH deficiency. J Endocrinol Invest 35(11):1021–1029PubMed
37.
go back to reference Tita P, Ambrosio MR, Scollo C, Carta A, Gangemi P, Bondanelli M, Vigneri R, degli Uberti EC, Pezzino V (2005) High prevalence of differentiated thyroid carcinoma in acromegaly. Clin Endocrinol (Oxf) 63(2):161–167CrossRef Tita P, Ambrosio MR, Scollo C, Carta A, Gangemi P, Bondanelli M, Vigneri R, degli Uberti EC, Pezzino V (2005) High prevalence of differentiated thyroid carcinoma in acromegaly. Clin Endocrinol (Oxf) 63(2):161–167CrossRef
38.
39.
go back to reference Gullu BE, Celik O, Gazioglu N, Kadioglu P (2010) Thyroid cancer is the most common cancer associated with acromegaly. Pituitary 13(3):242–248PubMedCrossRef Gullu BE, Celik O, Gazioglu N, Kadioglu P (2010) Thyroid cancer is the most common cancer associated with acromegaly. Pituitary 13(3):242–248PubMedCrossRef
40.
go back to reference dos Santos MC, Nascimento GC, Nascimento AG, Carvalho VC, Lopes MH, Montenegro R, Montenegro R Jr, Vilar L, Albano MF, Alves AR, Parente CV, dos Santos Faria M (2012) Thyroid cancer in patients with acromegaly: a case-control study. Pituitary 16(1):109–114CrossRef dos Santos MC, Nascimento GC, Nascimento AG, Carvalho VC, Lopes MH, Montenegro R, Montenegro R Jr, Vilar L, Albano MF, Alves AR, Parente CV, dos Santos Faria M (2012) Thyroid cancer in patients with acromegaly: a case-control study. Pituitary 16(1):109–114CrossRef
41.
go back to reference Vilar L, Naves LA, Costa SS, Abdalla LF, Coelho CE, Casulari LA (2007) Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly. Endocr Pract 13(4):363–372PubMedCrossRef Vilar L, Naves LA, Costa SS, Abdalla LF, Coelho CE, Casulari LA (2007) Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly. Endocr Pract 13(4):363–372PubMedCrossRef
42.
go back to reference Tolis G, Angelopoulos NG, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Protonotariou A, Lytras A (2006) Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. Neuroendocrinology 83(3–4):249–257PubMedCrossRef Tolis G, Angelopoulos NG, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Protonotariou A, Lytras A (2006) Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. Neuroendocrinology 83(3–4):249–257PubMedCrossRef
43.
go back to reference Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, Melmed S (2011) Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 14(3):284–294PubMedCentralPubMedCrossRef Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, Melmed S (2011) Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 14(3):284–294PubMedCentralPubMedCrossRef
44.
go back to reference Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P (2007) Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab 92(5):1743–1747PubMedCrossRef Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P (2007) Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab 92(5):1743–1747PubMedCrossRef
45.
go back to reference Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F (2005) Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 90(5):2731–2739PubMedCrossRef Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F (2005) Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 90(5):2731–2739PubMedCrossRef
46.
go back to reference Cambuli VM, Galdiero M, Mastinu M, Pigliaru F, Auriemma RS, Ciresi A, Pivonello R, Amato M, Giordano C, Mariotti S, Colao A, Baroni MG (2012) Glycometabolic control in acromegalic patients with diabetes: a study of the effects of different treatments for growth hormone excess and for hyperglycemia. J Endocrinol Invest 35(2):154–159PubMed Cambuli VM, Galdiero M, Mastinu M, Pigliaru F, Auriemma RS, Ciresi A, Pivonello R, Amato M, Giordano C, Mariotti S, Colao A, Baroni MG (2012) Glycometabolic control in acromegalic patients with diabetes: a study of the effects of different treatments for growth hormone excess and for hyperglycemia. J Endocrinol Invest 35(2):154–159PubMed
47.
go back to reference Bondanelli M, Ambrosio MR, degli Uberti EC (2001) Pathogenesis and prevalence of hypertension in acromegaly. Pituitary 4(4):239–249PubMedCrossRef Bondanelli M, Ambrosio MR, degli Uberti EC (2001) Pathogenesis and prevalence of hypertension in acromegaly. Pituitary 4(4):239–249PubMedCrossRef
48.
go back to reference Mishra M, Durrington P, Mackness M, Siddals KW, Kaushal K, Davies R, Gibson M, Ray DW (2005) The effect of atorvastatin on serum lipoproteins in acromegaly. Clin Endocrinol (Oxf) 62(6):650–655CrossRef Mishra M, Durrington P, Mackness M, Siddals KW, Kaushal K, Davies R, Gibson M, Ray DW (2005) The effect of atorvastatin on serum lipoproteins in acromegaly. Clin Endocrinol (Oxf) 62(6):650–655CrossRef
49.
go back to reference Jallad RS, Bronstein MD (2009) Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide. Neuroendocrinology 90(1):82–92PubMedCrossRef Jallad RS, Bronstein MD (2009) Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide. Neuroendocrinology 90(1):82–92PubMedCrossRef
50.
go back to reference Vilar L, Azevedo MF, Naves LA, Casulari LA, Albuquerque JL, Montenegro RM, Montenegro RM Jr, Figueiredo P, Nascimento GC, Faria MS (2011) Role of the addition of cabergoline to the management of acromegalic patients resistant to long-term treatment with octreotide LAR. Pituitary 14(2):148–156PubMedCrossRef Vilar L, Azevedo MF, Naves LA, Casulari LA, Albuquerque JL, Montenegro RM, Montenegro RM Jr, Figueiredo P, Nascimento GC, Faria MS (2011) Role of the addition of cabergoline to the management of acromegalic patients resistant to long-term treatment with octreotide LAR. Pituitary 14(2):148–156PubMedCrossRef
Metadata
Title
Multiple facets in the control of acromegaly
Authors
Lucio Vilar
Alex Valenzuela
Antônio Ribeiro-Oliveira Jr.
Claudia M. Gómez Giraldo
Doly Pantoja
Marcello D. Bronstein
Publication date
01-01-2014
Publisher
Springer US
Published in
Pituitary / Issue Special Issue 1/2014
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-013-0536-7

Other articles of this Special Issue 1/2014

Pituitary 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.